Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain scan could reveal hidden signs of long COVID

NCT ID NCT06223971

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special PET scan tracer is safe for people with Long COVID. Six adults with a history of COVID-19 (some with ongoing symptoms, some without) received the tracer and MRI scans. The goal was to see if the tracer can highlight brain inflammation differences between those with and without Long COVID symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

6 people

The number who actually took part.

Started

Aug 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) \[per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling\] and comply with the study procedures. 2. Documented history of COVID infection at least 6 - 12 months before enrollment. 3. Men and women at least 18 years old. 4. Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy, oophorectomy or surgical sterilization). 5. Geographic accessibility to the study center and the ability to travel to the clinic for study visits. 6. Agrees to the visit schedule as outlined in the informed consent. 7. Pre-study labs within normal range, or if abnormal, deemed not clinically significant by the site investigator. Exclusion Criteria: 1. History of recent nosocomial infection. 2. History of chronic neurological disorder, such as epilepsy, or structural Central Nervous System (CNS) abnormality such as stroke or arteriovenous malformation. 3. History of head trauma with prolonged loss of consciousness (\>10 minutes) or any neurological condition including stroke, seizure (excluding childhood febrile seizure), or visible structural abnormality on prior MRI. 4. Active or recent (in the past year) substance dependence (drugs-including nicotine, marijuana or alcohol). 5. Receipt of any investigational drug, device or biologic within 30 days of administration of study compound. 6. Use of anti-inflammatory medications, immunosuppressants, or benzodiazepines within 7 days of administration of study compound. 7. Any concomitant medical disease or condition limiting the safety to participate including, but not limited to: * Coagulopathy * Active infection 8. Contraindications to MRI scanning to include pacemakers, metallic implants/prosthesis or prohibitive claustrophobia, etc. 9. Contraindications to PET scanning to include pregnancy, etc. 10. Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject. 11. Any radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem. 12. Any history of learning disability or special education (due to the potential to affect performance on neuropsychological testing).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID long-haul are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins Outpatient Center

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.